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Abstract 
Background  
Ameloblastoma is a slow growing, locally invasive, benign tumour of odontogenic origin. 
Ameloblastoma is the most common odontogenic tumour with varying recurrence rates, 
depending on the adequacy of the tumour removal. A number of factors including inadequate 
removal of tumour have been associated with recurrence 
 
Aim 
The aim of the study was to determine the prevalence of recurrent ameloblastoma in patients 
treated at the Wits Oral Health Centre. 
 
Methods  
This study was a retrospective analysis of 246 records of patients diagnosed with 
ameloblastoma over a 24 year period (January 1992 to December 2015) in order to determine 
factors associated with recurrence. Descriptive statistics of mean, standard deviation, 
frequencies, percentages and proportions were used to summarize the data. Chi- squared and 
multivariate logistic regression was used to determine the association between the variables 
and recurrence associated with AMB. 
 
Results  
Males (49.6%) and females (50.4%) were equally affected with a mean age of 31 years (range 
7-82 years). AMB affected the mandible (96%) more than the maxilla (4%). Multicystic 
AMB represented the majority (76.8%) of cases. Most AMB’s (92.7%) presented with bone 
perforation. Nineteen cases (7.7%) recurred, mostly in soft tissues, fifteen of which were 
treated radically and four conservatively. Fifteen (78.95%) recurrent AMB’s presented within 
10 years of surgical treatment with the remainder (2, 1 and 1) presenting 13, 17 and 21 years 
post-treatment, respectively. AMB’s larger than 4cm in greatest diameter were associated 
with 84.21% of the recurrences. Multicystic AMB accounted for 84.21% of the recurrences. 
 
Conclusions  
This study is in agreement with most studies with regard to demographic data and clinico-
pathological features of AMB. Large multicystic AMB with soft tissue encroachment have a 
high propensity to recur even when treated by radical resection. Recurrence is a significant 
associated with histological margins and the surgical method of treatment. 
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Chapter 1 
Introduction 
 
Ameloblastoma is a slow growing, locally invasive, benign tumour of odontogenic origin 
(Odeli et al., 2017). It was formerly known as an adamantinoma (Ivery et al., 1930). The first 
author to describe this tumour was Cusack in 1827. Globally, it has been estimated to affect 
0.5 cases per million persons per year (Larsson et al., 1978). Keszler and Dominguez., (1986), 
reported that 10-15% of ameloblastoma occur in childhood. The tumour comprises 
approximately 1% of oral-maxillofacial tumours (Neville et al., 2016) and 14% of all 
odontogenic tumours (Lasisi et al., 2013: Oginni et al., 2015). 
 
Ameloblastoma is the most common tumour in Africa (Mosadomi A., 1975) and Asia (Lu et 
al., 1998; Kim and Jang., 2001) while in Western countries such as the United States and 
Canada; the odontoma is the most common followed by ameloblastoma (Regezi et al., 1978; 
Daley at el., 1994).  
 
The peak incidence is between the 3rd and 7th decades of life (Neville et al., 2016). Olusanya 
et al., (2013) in Nigeria, reported a mean age of 34.2 years while Oomens and van der Waal., 
(2014) in Netherlands, reported a mean age of 44.1 years. Males and females are equally 
affected. Nearly 85% of ameloblastomas occur in the mandible, most often in the posterior 
area. (Neville et al., 2016) 
 
The aetiology of ameloblastoma is unknown; although, multiple factors including trauma, 
inflammation, nutritional deficiency, non-specific irritation from extractions and dental caries 
have been implicated (Brown and Betz., 2015). Ameloblastoma may arise from rests of 
Malassez and Serres, reduced enamel epithelium, the epithelial lining of an odontogenic cyst, 
or from the basal cells of the oral mucosa (Neville et al., 2016) 
 
Two recurrent mutations associated with the molecular pathogenesis of ameloblastoma 
involving the mitogen-activated protein kinase (MAP) and sonic hedgehog (SHH) pathways 
have been identified (Kurppa et al., 2014; Brown et al., 2014; Sweeney et al 2014). The most 
common mutation in the MAPK pathway is the BRAFV600E mutation seen mostly in the 
mandibular ameloblastomas, while the smoothened (SMO) mutation is associated with 
maxillary ameloblastomas. The identification of these mutations has led to studies that 
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demonstrated the efficacy of BRAF inhibitor therapy for ameloblastomas with BRAFV600E 
mutations (Kaye et al., 2015, Faden et al., 2017)  
  
Literature review 
 
The World Health Organisation 2017 classification of odontogenic tumours (WHO, 2017) 
classified ameloblastomas into conventional, extraosseous / peripheral, unicystic, and 
metastasizing ameloblastomas. Conventional ameloblastoma has replaced solid/multicystic 
ameloblastoma in the 2015 WHO classification of odontogenic tumours (El-Naggar et al., 
(2017). The desmoplastic ameloblastoma is no longer deemed a separate clinicopathological 
entity but a variant of ameloblastoma. The classification of ameloblastic carcinoma as the 
malignant counterpart of the benign ameloblastoma has been retained; metastasizing 
ameloblastoma has however been classified benign and removed from the malignant category, 
chiefly due to indistinguishable histological features between primary metastasizing 
ameloblastoma, it’s metastatic counterpart and benign ameloblastoma (Wright and Vered., 
2017). 
 
Solid/multicystic or conventional ameloblastoma has a peak incidence in the fourth and fifth 
decades of life. Males and females are affected equally (WHO, 2017). While most studies 
report a predilection for the African population, a few have reported no racial predilection 
(Simon et al., 2005; Oginni et al., 2015). Approximately 80% to 85% of multicystic 
ameloblastoma involve the mandible and 15% to 20% affect maxilla (Neville et al., 2016).  
 
Early solid/multicystic or conventional ameloblastoma is often asymptomatic; smaller lesions 
may only be detected on radiographs. However, the more common presentation is that of a 
slow growing, painless mass with cortical expansion (Adebiyi et al., 2006).  Large tumours 
may be asymptomatic (Neville et al., 2016) or present with loose teeth, malocclusion, 
paraesthesia, pain, soft tissue infiltration, facial deformity, trismus, dysphagia, and airway 
obstruction (WHO, 2017). Solid/multicystic ameloblastoma radiologically presents as a well 
corticated, multilocular radiolucency with a soap-bubble or honeycomb appearance (Oginni et 
al., 2015).  
 
Multicystic ameloblastoma has variable cystic and solid components; histologically the 
tumour is characterised by a follicular or plexiform growth pattern with various histological 
types (Neville et al., 2017). The histological types of ameloblastoma include acanthomatous, 
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granular, basaloid, and desmoplastic may be admixed in the same tumour El-Naggar et al., 
(2017). 
 
Robinson and Martinez (1977), described unicystic ameloblastoma as a well circumscribed 
unilocular, radiolucent tumour that has a better prognosis than multicystic ameloblastoma. 
The incidence of unicystic ameloblastoma peaks in the second decade of life. The tumour has 
a male predilection and comprises 5-22% of all ameloblastomas (Philipsen et al., 2001). It 
most commonly presents as painless jaw expansion.  
 
Unicystic ameloblastoma is histologically classified into luminal, intraluminal, and mural 
subtypes (Ackermann et al., 1988). The epithelium of the luminal unicystic ameloblastoma is 
confined to the luminal surface. In the Intraluminal unicystic ameloblastoma, the epithelium 
proliferates into the lumen and forms what protrude into the cyst lumen (Regezi et al., 1978). 
 
 The mural unicystic ameloblastoma is characterized by epithelial proliferation into the 
surrounding fibrous connective tissue wall. The infiltrative nature of the mural unicystic 
ameloblastoma renders it more aggressive than the other two unicystic ameloblastoma types. 
and similarly, aggressive as the solid/multicystic ameloblastoma.    
 
The peripheral or extraosseous ameloblastoma variant is a benign neoplasm that occurs 
exclusively in the gingiva; it originates from either extraosseous remnants of the dental 
lamina or the basal cell layer of surface epithelium (Buchner and Sciubba., 1987). Peripheral 
ameloblastoma is rare and accounts for about 1 to 10% of the ameloblastoma variants and 
affects males more frequently than females (Philipsen et al., 2001). Histopathologically, 
peripheral ameloblastomas have the same features as the intraosseous form of the 
ameloblastoma (Barnes et al., 2005). Recurrence rates between 15% and 20% have been 
reported (Pogrel et al., 2009). Recurrent and primary peripheral ameloblastoma are treated by 
local excision (Pogrel et al., 2009). Malignant transformation of a peripheral ameloblastoma 
is infrequent (Neville., 2016).  
  
Although some authors support conservative treatment of all ameloblastoma variants, many 
are in disagreement as a result of the more aggressive nature of the multicystic ameloblastoma 
and support radical treatment of multicystic ameloblastoma (Nakamura et al., 2002). Radical 
management of multicystic ameloblastoma involves resection of 1 to 1.5 cm of seemingly 
unaffected bony margins and adjacent soft tissue (Carlson and Marx, 2006; Pogrel et al., 
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2009). They also reported 60-80% of recurrence rate following conservative management. 
Hertog et al., (2010) supported the radical approach with wider resection margins of 1.5 to 
2cm of uninvolved bony margins. Muller and Slootweg (1985) reported a 5-15 % recurrence 
rate following radical resection including adjacent soft tissues. Sehdev et al., (1974) reported 
a 90% - 100% recurrence rate following curettage of ameloblastomas.  
 
Unicystic ameloblastomas are treated conservatively or radically, depending on the preference 
of the surgeon (Neville et al., 2016). Concerning management of unicystic ameloblastoma, 
Seintou et al., (2014) observed good prognosis following conservative management of 
luminal unicystic ameloblastoma in a paediatric population sample. In contrast, intraluminal 
and mural type frequently resulted in recurrence. While Hirschhorn (2013) advocated a 
conservative approach in children with unicystic ameloblastoma and reserved the radical 
approach for recurrences, Swapnil et al., (2014), recommended radical resection of unicystic 
ameloblastomas in order to avoid further complications and recurrence. Georgios et al., 
(2014) suggested that smaller lesions be managed conservatively, even though the radical 
approach is the preferred treatment modality. Pogrel et al., (2009), recommended enucleation, 
curettage and physicochemical treatment with liquid nitrogen or Carnoy’s solution. Radical 
treatment is recommended only if liquid nitrogen or Carnoy’s solution is not available with 
resection margins of 0.5- to 1-cm (Pogrel et al., 2009). 
 
 Lee et al., (2004), suggested that the use of Carnoy’s solution after enucleation of unicystic 
ameloblastoma is adequate; however, they reported a 10% recurrence rate. Lau et al., (2006) 
in their systematic review, reported recurrence rates of 3.6% for resection, 30.5% for 
enucleation and 16% for enucleation followed by Carnoy’s solution for the management of 
unicystic ameloblastoma. 
 
More than 50% of recurrences are diagnosed in the first year following primary surgery 
(Reichart et al., 1995; Olaitan et al., 1998; Hertog et al., (2010) However, Eckardt et al., 
(2009), recommended long term follow-up. Incomplete removal of ameloblastoma facilitates 
the spread of residual tumour cells leading to recurrence (To et al., 2002). Of the histological 
types follicular, granular, and acanthomatous had high recurrence, while desmoplastic had 
low recurrence; the plexiform growth pattern had lower recurrence than follicular, and 
unicystic ameloblastoma showed lower recurrence rates than multicystic ameloblastoma 
(Hong et al., 2007). According to Pogrel and Montes (2009), histological types are of no 
prognostic significance and demonstrate no association with ameloblastoma recurrence. 
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Hertog et al., (2010) demonstrated an association between recurrence and the method of 
surgical treatment; and no association between recurrence and the histological type. Abdel-
Aziz and Amin (2012) reported a significant association between CD10 expression and Ki67 
labeling index and ameloblastoma recurrence. Sweeney et al., (2014) suggested that SMO 
gene mutation appears to be associated with recurrence. Ameloblastic carcinoma is an 
uncommon malignant odontogenic tumour with a predilection for the posterior mandible and 
male patients above 45 years. The ameloblastic carcinoma may arise de novo or from a pre-
existing peripheral or intra-osseous ameloblastoma (WHO, 2017). Clinically it may present 
with rapid growth, perforation of the cortex, infiltration of adjacent structures, cortical 
expansion and pain. Radiologically ameloblastic carcinoma is ill-defined and may show 
cortical destruction (Neville et al. 2016). 
 
Histologically, ameloblastic carcinoma shows cytological atypia and the histological patterns 
of an ameloblastoma. Most metastases present in the lungs; cervical lymph node metastases 
are unusual (Kruse et al., 2009). The median survival rate is 17.6 years. The maxillary 
tumours are twice more likely to cause death than mandibular tumours (Rizzlitelli et al., 
2015). Radical surgical excision is associated with a local recurrence of 28%. According to 
Yoon et al., (2009) radiotherapy is of little value in the management of this malignancy. 
Haung et al., (2014), however, advocates radiation therapy for management of ameloblastic 
carcinoma. Aggressive multimodality treatment is recommended (Li et al., 2014). 
 
Metastasizing ameloblastoma is defined as a solid or multicystic ameloblastoma that 
metastasises despite its benign histological appearance. It represents 2% of benign 
ameloblastoma (Dissanayeke et al., 2011; Verneuli et al., 2002), and frequently involves the 
posterior mandible. Ameloblastic carcinoma and metastasizing ameloblastoma predominantly 
present in African males (Rizzitelli et al., 2015). The overall incidence is 1.79 cases per 10 
million population per year.  
 
Similar to ameloblastic carcinoma metastatic deposits are common in lung, followed by 
lymph nodes and bone (Dissanayeke et al., 2011). Approximately 50% of cases with 
metastases and long-term follow-up have died of their disease (Neville et al., 2016). Prognosis 
is poor and overall 5-year survival is 70%, depending on the site of metastatic deposits and 
surgical ease of access. Rizzitelli et al., (2015) reported that radiotherapy and chemotherapy 
have shown no benefit, the authors advocate neck dissection for cervical metastasizing 
ameloblastoma. 
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Aim  
 
To determine the prevalence rate, clinic-pathologic and demographic factors that influence the 
recurrence of ameloblastoma in patients treated at the Wits Oral Health Centre. 
 
Objectives 
 
I. To describe clinicopathological and demographic features that affect the recurrence of 
ameloblastoma.  
 Histological type and growth patterns associated with recurrence. 
 Relationship between tumour size and recurrence. 
 Surgical treatment procedures associated with recurrence. 
 Patient demographics which includes age, gender and site of occurrence  
II. To assess the prevalence rate in our unit in relation to what is reported in the literature  
 
Rationale for the study 
 
Recurrence rates are indicative of the inadequacy of the treatment procedure and may help 
inform the review of protocols for optimal management of ameloblastomas. Knowledge 
gained in determining factors associated with recurrence will help in reviewing 
ameloblastoma management protocols in order to minimize or prevent recurrences. 
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CHAPTER 2 
RESEARCH METHODOLOGY 
 
 INTRODUCTION 
 
In this chapter, we focus on the materials and methods used to conduct the study. This study 
was implemented in phases. A proforma was designed to enable the principal investigator to 
collect data. Permission to conduct the study was granted by various stakeholders prior to 
collection of data. The following phases are elaborated thoroughly: study design, study 
setting, inclusion and exclusion criteria, data collection, data analysis and ethical 
consideration. 
 
Study design 
 
A retrospective, cross-sectional, descriptive study was conducted on records of patients 
treated for ameloblastomas in the last twenty-four years (January 1992- December 2015).  
 
Study setting 
 
This study was conducted at the Wits Oral Health Centre, School of Oral Health Sciences, 
Faculty of Health Sciences at the University of the Witwatersrand. Only cases that were 
treated for ameloblastoma in the Department of Maxillofacial and Oral Surgery at their two 
academic facilities in Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani 
Baragwanath Academic Hospital were considered. The Wits Oral Health Centre is situated in 
Johannesburg in the Gauteng province of the Republic of South Africa. Both hospitals submit 
biopsy specimen to the Department of Oral Pathology for microscopic examination and 
histopathological diagnosis. Data was extracted from the histopathological reports in the 
archives of the Department of Oral Pathology and from theatre notes.  
 
Surgical protocol 
 
The surgical protocol followed for radical resection of ameloblastomas in the Department of 
Maxillofacial and Oral Surgery has been reported (Ferretti et al., 2013). Surgical dissection is 
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supra-periosteal in the presence of cortical bone perforation or subperiosteal in the absence of 
cortical perforation. The tumour is resected 1-2 cm into uninvolved bone. A custom made 2.4 
mm titanium reconstruction plate is used to reconstruct the bony defect. In cases, where 
disarticulation of the condyle is performed, a prosthesis called the ‘Ferretti condyle’ is used to 
replace the resected condyle, while a spacer is used to maintain the space of the mandibular 
defect in order to expedite secondary reconstruction phase. In the first seven days post-
surgery, the patient feeds through a nasogastric tube. Maxillomandibular fixation (MMF) is 
applied for six weeks in order to prevent movement and is followed by reconstruction 
surgery. A particulated corticocancellous bone graft is harvested from the iliac crest bone and 
grafted to the mandibular defect; a costochondral graft is used to replace the ‘Ferretti 
condyle’. MMF is then applied again for six more weeks during the healing phase of the graft. 
Implants are placed four months post the reconstruction phase, followed by rehabilitation with 
implant supported prosthesis. Six monthly reviews are conducted in first year of treatment 
followed by lifetime annual review. The surgery is performed by senior consultants assisted 
by senior registrars in the Department of Maxillofacial and Oral Surgery.  
 
 Inclusion criteria 
 
The following inclusion criteria were used: 
 A diagnosis of ameloblastoma must have been confirmed histologically by an oral 
pathologist. 
 All patients treated for ameloblastomas from January 1992 - December 2015. 
 All treatment modalities of ameloblastomas were included. 
 All histological types of ameloblastomas treated were included. 
 All ameloblastomas presenting in the mandible, maxilla and skull areas were 
included. 
 
 Exclusion criteria 
 
The following exclusion criteria were used: 
 Missing records. 
 More than 20% missing data on variables for each case. 
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Data collection 
 
A proforma (data collection tool) was design in order to assist in extraction of data. The 
following variables were included, age, gender (male/female), site of the tumour 
(mandible/maxilla/skull), tumour location (anterior/posterior), size of the tumour (less than 
4cm/greater than 4cm), involvement of the inferior border (mandible) by the tumour (yes/no), 
tumour bony perforation (yes/no), ameloblastoma variant (unicystic/multicystic/peripheral), 
subtypes of unicystic ameloblastoma (luminal/intraluminal/mural), growth patterns of 
multicystic ameloblastoma (follicular/plexiform), histological types of multicystic 
ameloblastoma (basal/granular/acanthomatous/desmoplastic), treatment option 
(enucleation/enucleation and peripheral ostectomy/enucleation, peripheral ostectomy and 
cryotherapy/marginal resection/complete resection), histological margins (bone clear/not 
clear/soft tissue clear/not clear), site with close margins 
(buccal/lingual/inferior/proximal/distal), recurrence (yes/no), site of recurrence (primary 
bone/soft tissue/grafted tissue), time between primary surgery and recurrence (See annexure 
A). 
 
Data analysis 
 
Data was captured into a Microsoft excel spreadsheet and subsequently exported to Stata 
IC/14 software for analysis. Descriptive statistics of mean, standard deviation, frequencies, 
percentages and proportions were used to summarize the data.  
Inferential statistics of Chi-squared test was used to determine the association between the 
categorical variables. Multivariate logistic regression was performed to determine the 
predictors of ameloblastoma recurrence. All statistical analysis was performed using a two-
sided test at 0.05 level of significant. 
 
 Ethical consideration 
 
Ethical clearance was obtained from both the Human Research and Ethics Committee 
(HREC) of Witwatersrand University and the Hospital Research and Ethics Committee (Wits 
Oral Health Centre) prior to data collection. The HREC clearance certificate was issued with 
reference no: M150841 (see Annexure B). The Hospital Research and Ethics Committee 
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reference no: WOHC/HREC/OCT/2015/03 (see Annexure C). Permission was also granted by 
the Head of the Department of Oral Pathology (see Annexure D). Strict confidentiality was 
adhered to. Codes were allocated to patient histological reports in order to protect patient 
identity. All patient identifiers were removed and kept on a separate link form (see Annexure 
E). Patient identifiers are only accessible to the principal investigator. 
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CHAPTER 3 
 
General overview of treated ameloblastomas at Wits Oral Health Centre between the years 
1992-2015 
 
The study evaluated the histopathological reports of 254 ameloblastoma cases treated at the 
Wits Oral Health Centre from 1992 to 2015. More than 20% of the assessed variables were 
missing in eight cases which were thus excluded from the study. A total of 246 
histopathological reports fulfilled the inclusion criteria. Males (49.6%) and females (50.4%) 
were equally represented (Table 3.1). 
 
Table 3.1 Gender distribution of ameloblastoma 
 
GENDER NO OF PATIENTS PERCENT 
Female 124 50.4 
Male 122 49.6 
 
The mean age for ameloblastoma diagnosis was 31 years (age range: 3-82 years) (Fig 3.1). 
Most cases presented in the third decade of life (34.6%) followed by the second (21.5%), and 
fourth (18.70%) decades. 
 
 
Fig 3.1 Age at treatment (in years) distribution of ameloblastoma  
 
0.4%
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34.6%
18.7%
10.6%
7.3%
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1.2% 0.4%
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The majority (96%, n=235) of cases presented in the mandible while 4,47 % presented in the 
maxilla (Fig 3.2). 
 
 
Figure 3.2 Anatomical site of involvement 
 
The size of the tumour was recorded in 244 cases. Of these, 85% (209) were 4 cm or larger in 
greatest diameter and 14% were less than 4cm. (Fig 3.3). 
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Figure 3.3 Size of ameloblastoma 
The majority of the ameloblastomas (92.7%), had perforated the bone and encroached on the 
soft tissues at the time of treatment. (Fig 3.4).  
 
 
Figure 3.4 Bone perforation by ameloblastoma  
 
Of the 246 cases, 231 were diagnosed as benign AMB’s comprising 189 multicystic, 41 
unicystic and one peripheral ameloblastoma, one adenoid ameloblastoma with dentinoid ghost 
cells, two malignant ameloblastomas; 13 cases were not subtyped.  (Fig 3.5).  
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Figure 3.5 Ameloblastoma variants 
Ameloblastoma variants, growth patterns and histological types were not specified in 
125(51%) cases. Thirty-nine (95.12%) unicystic ameloblastomas were subtyped into luminal 
(28.20%, n=11), intraluminal (17.95%, n=7), and mural (53.85%; n=21). The growth pattern 
was reported in 67 cases of multicystic ameloblastoma and included follicular (28), plexiform 
(8) and mixed follicular-plexiform (26). The histological subtypes reported include basal, 
granular, acanthomatous and desmoplastic ameloblastoma (Table 3.2). 
 
Table 3.2 Ameloblastoma variants, growth patterns and histological types 
SUBTYPE FREQUENCY PERCENT 
Not available 125 51 
    UNICYSTIC VARIANT 
Luminal 11 5 
Intraluminal 7 3 
Mural 21 9 
TOTAL: 39   
GROWTH PATTERNS OF MULTICYSTIC AMELOBLASTOMA 
Follicular 28 9 
Plexiform 13 3 
Follicular and plexiform 26 9 
TOTAL 67   
HISTOLOGICAL TYPES OF MULTICYSTIC OF MULTICYSTIC 
AMELOBLASTOMA 
Basal 6 1 
Granular 20 3 
Acanthomatous 1 0 
Desmoplastic 1 0 
TOTAL: 28   
 
 
Of the 246 cases, 244 were treated either conservatively or radically. The treatment option 
could not be discerned in 2(0.2%) cases. Twenty-eight cases were treated conservatively; 8 
(3.3) by enucleation only, 17(6.9%) by enucleation and peripheral ostectomy, 2 by 
marsupialization and 1(0.4%) by excision. Of the 216 cases treated radically, 213 were 
completely resected while 3 were marginally resected (Fig 3.6).  
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Figure 3.6 Treatment options for ameloblastoma 
 
 
The assessment of histological margins was carried out in radically treated cases only. The 
nature of the histological margins was not reported in 10 cases. The bone and soft tissue 
margins were reported to be clear in 135 cases. The soft tissue margins were not clear in 63 
cases, while bony margins were not clear in 7. In one case both the bony and soft tissue 
margins were not clear (Table 3.3). 
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Table 3.3 Nature of histological margins of ameloblastoma 
MARGIN FREQUENCY PERCENT 
Not available 3 4.63 
Clear 135 62.5 
Soft tissue not clear 63 29.17 
Bone not clear 7 3.24 
Bone and soft tissue not 
clear 
1 0.46 
 
 
Of the 246 patients treated either conservatively or radically, 7 % (n=19) presented with 
recurrent ameloblastoma. No recurrence was recorded in the remaining 227 patients (92.3%), 
however, most patients were lost to follow up (Table 3.4). 
 
Table 3.4 Recurrence rate of ameloblastoma 
RECURRENCE FREQUENCY PERCENT 
No 227 92.3 
Yes 19 7.7 
 
3.2.1. Association between clinicopathological factors and recurrence 
 
The mean age of patients with recurrent AMB was 33 years (range: 7 -61 years). Most 
recurrences occurred in the third (n= 5; 26.32%) and fifth (n=4; 21.05%) decades of life. The 
first and seventh decades were the least affected. (1%) (Table 3.5). 
 
Table 3.5 Association between age and recurrence 
AGE NO OF PATIENTS PERCENT 
0-9 1 5.26 
10-19 3 15.79 
20-29 5 26.32 
30-39 3 15.79 
40-49 4 21.05 
50-59 2 10.53 
60-69 1 5.26 
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Although ameloblastoma showed no significant gender predilection, 63% of the recurrences 
occurred in females (Table 3.6).  
 
Table 3.6 Association between gender and recurrence 
GENDER NO OF PATIENTS PERCENT 
Female 12 63.16 
Male 7 36.84 
 
Three sites of recurrence were identified: primary bone, soft tissue and grafted tissue. Most of 
the recurrences occurred in soft tissue (52.63%), 31.58%% in primary bone and 15.79% cases 
in grafted tissue (Fig 3.7). 
 
 
Figure 3.7 Site of recurrence 
 
Fifteen (78.95%) recurrent ameloblastomas presented within 10 years of the surgical 
treatment with the remaining three cases presenting 13, 17 and 21 years post treatment. (Table 
3.7) 
 
 
 
 
 
Primary bone
31.58%(6)
Soft tissue
52.63%(10)
Grafted tissue
15.79%(3)
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Table 3.7 Association between post-surgical treatment period and recurrence  
RECURRENCE TIME 
(YEARS) 
FREQUENCY PERCENT 
1 4 21.05 
3 2 10.53 
4 2 10.53 
8 4 21.05 
9 2 10.53 
10 1 5.26 
13 2 10.53 
17 1 5.26 
21 1 5.26 
 
 
 
Most recurrent ameloblastomas had perforated the bone at the time of treatment (n=16; 
84,21%), with only 3 (15.79%) not demonstrating bone perforation. (Table 3.8). 
Ameloblastomas larger than 4cm in greatest diameter showed a high propensity to recur (84, 
21%) (Table 3.9). 
 
  
Table 3.8 Association between bone perforation and recurrence 
Bone perforation Frequency Percent 
No 3 15.79 
Yes 16 84.21 
 
 
Table 3.9 Association between tumour size and recurrence 
Size of the tumor Frequency Percent 
Less than 4cm 3 15.79 
Greater than 4cm 16 84.21 
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3.2.2. Association between the clinicopathological and demographic variables and 
recurrence  
 
Table 3.10 Chi-squared test of association  
Variables  Pearson chi2 P-value 
Age 6.17 0.63 
Gender 1.34 0.25 
Site 1.77 0.18 
Size 0.21 0.90 
Bone perforation 2.18 0.14 
Ameloblastoma variant 2.23 0.82 
Subtype   26.7 0.063 
Treatment option 17.03 0.009 
Histological margins 19.57 0.001 
 
Chi-square test of association was performed between the clinicopathological and 
demographic variables (age, gender, site, size, bone perforation, type, subtype, treatment 
option, histological margins) and ameloblastoma recurrence. The association between 
recurrence and ameloblastoma subtypes was marginally significant (p=0.063). The 
association between treatment option and the nature of histological margins was statistically 
significant (p = 0.009 and p= 0.001 respectively). 
 
Multivariate logistic regression analysis was performed to determine the risk of recurrence. 
The clinicopathological and demographic variables with p values ≤ 0.01 from the chi-squared 
analysis were entered into logistic regression. 
 
Table 3.11 Multivariate logistic regression analysis for the risk of recurrence  
Variable Odds ratio P-value 95% Confidence interval 
Site  0.094 0.329 -0.095      0.284        
Bone perforation 0.055 0.500 -0.106      0.217 
subtype -0.002 0.534 -0.010      0.004 
Treatment option -0.013 0.703 -0.083      0.056 
Histological margin 0.094 0.011 0.037       0.152 
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Treatment option, ameloblastoma subtype and bone perforation had the highest significant p-
values (p=0.703, p=0.534 and p=0.500) respectively and were eliminated. The second logistic 
regression was performed. 
 
Table 3.12 Second multivariate logistic regression analysis for the risk of recurrence 
Variable Odds ratio P-value 95% Confidence interval 
Site  0.082 0.370 -0.098      0.263       
Histological margin 0.084 0.002 0.030       0.139 
 
 
The site of involvement showed a statically insignificant association with recurrence (p value 
=0.370). Histological margins showed a statistical significant association with recurrence (p 
value = 0.002). Histological margins have a 0.08 likelihood to be associated with recurrence 
at 95% CI (0.030-0.139). 
 
3.2.3. Association between surgical treatment option and recurrence  
 
Fifteen (78.95%) of the 19 cases that recurred were radically treated by complete resection 
while 4 were treated conservatively. Of the 4 conservatively treated cases, 1 (5.26%) was 
marsupialised, and 3 (15.79%) enucleated (Fig 3.8). 
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Fig 3.8 Association between surgical procedure option and recurrence  
 
 
Three (11%) unicystic and 16 (89%) solid/ multicystic ameloblastomas presented with 
recurrence (Fig 3.9). The unicystic ameloblastomas comprised one mural and two 
intraluminal subtypes. Of these, two were mixed follicular and plexiform, two were follicular 
and the growth pattern of the remaining three is unknown. Reported histopathological 
subtypes include granular, and acanthomatous. (Table 3.13) 
 
 
 
 
 
Enucleation
15.79%(3)
Radical resection
78.95%(15)
Marsupialisation
5.26%(1)
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Figure 3.9 Association between ameloblastoma variants and recurrence 
 
Table 3.13 Association between histological type of ameloblastoma, growth pattern and 
recurrence 
 
SUBTYPE FREQUENCY PERCENT 
Not available 9 47.37 
Intraluminal 2 10.53 
Mural 1 5.26 
Follicular 2 10.53 
Granular 2 10.53 
Acanthomatous 1 5.26 
Follicular and plexiform 1 5.26 
Follicular and plexiform and 
granular 
1 5.26 
 
 
 
 
 
 
Unicystic
11%(3)
Multicystic
89%(16)
TYPE
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Chapter 4 
 
Introduction 
 
In this chapter, we discuss the current results compared to the findings of previous studies. 
We summarise our outcomes which form the basis of recommendations made. Limitations are 
acknowledged and reflected upon. 
 
Discussion 
The incidence of ameloblastoma in South Africa is 2.4-fold higher than the global incidence 
per million population per year (Shear et al., 1978). Several West African studies (Sawyer et 
al., 1985; Odukoya et al., 1995; Ajayi et al., 2004) have reported similar findings. The 
reported discrepancies in the relative frequency of ameloblastoma and clinicopathological 
features have been attributed to genetic and external factors (Philipsen et al., 1998).  
Contrarily, a study from Tanzania, East Africa reported an ameloblastoma incidence of 0.68 
per million per year, similar to those reported in European countries such as the Netherlands 
and Sweden (Simon et al., 2005). This finding was confirmed by Oginni et al., (2015) who 
conducted a prospective study of patients presenting with odontogenic tumours at all Oral and 
Maxillofacial Departments in Nigeria. The authors reported a relative frequency of 0.76 per 
million per year comparable to the global incidence of 0.5 per million per year. 
Ameloblastoma is the most common benign odontogenic tumour in China (Lu et al., 1998) 
and Africa (Mosadomi, 1995; Barnes et al., 2005) 
 
Age 
In this study, the age at treatment ranged from 7-82 years with a mean age of 31 years. 
Similarly, Adeline et al., (2008), in their 10-year audit of ameloblastoma in Kenya, reported a 
mean age of 30.2 years while Olaitan et al., (1993) reported a mean age of 30 years at the time 
of treatment. Santos et al., (2014), in their review of 112 cases of ameloblastoma, reported a 
slightly higher mean age of 35.1 years. Multicystic ameloblastoma is rarely seen in the first 
two decades of life, conversely unicystic ameloblastomas occurs earlier in life, mostly in the 
second decade (Neville et al., 2016).  
Only 21.05% recurrences were detected in patients younger than 20 years. This study found 
that the mean age at recurrence was 33.32 years (range: 7-61 years). This is lower than the 
26.4 years (range, 11-52 years) reported in a Korean study (Kim and Young., 2001). No 
significant association was documented between age and recurrence. 
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Gender 
 
Although most recurrences presented in females, no statistically significant association was 
found between recurrence and gender as documented in other studies (Abdel-Aziz and Amin., 
2012; Ahlem et al., 2015; Hong et al., 2007). No significant gender predilection was seen in 
primary ameloblastoma with 50, 4% females and 49, 6% males. This result concurs with the 
findings of numerous published series (Simon et al., 2005; Ladeinde et al., 2006; Okada et al., 
2007; Adeline et al., 2008; Gunawardhana et al., 2010;). However, some studies, particularly 
in Africa and Asia have reported a male predilection. Olaitan et al., (1993) documented 61.9% 
ameloblastomas presenting in males and 38.1% in females. This finding corroborates that of 
Kim and Jang (2001) who reported 55% males and 45% females in a Korean sample. 
Furthermore, in India, Nalabolu et al., (2016), reported a male predilection with 69, 6% males 
afflicted by ameloblastoma.  
 
Localisation 
 
There is consensus amongst researchers that ameloblastomas have a predilection for the lower 
jaw with approximately 80% presenting in the mandible in most studies (McClary et al., 
2015). Mandibular predilection as high as 87.3% (Kim and Young., 2001) and 92% (Ahlem et 
al., 2015) has been reported. The findings in the abovementioned studies corroborate my 
results which showed 96% mandibular involvement. Nevertheless, noteworthy discrepancies 
in the mandible-maxilla ratios have been demonstrated. The mandible-maxilla ratio in this 
study was 1: 0.05 while in Egypt and Nigeria, Tawfik et al., (2010) and Adebiyi et al., (2006) 
reported ratios of 1: 0.1 and 1: 0.03 respectively. In Sri Lanka, ratios of 1: 0.06 and 1: 0.13 
were reported three years apart by different authors (Okada et al., 2007; Gunawardhana et al., 
2010). This study documented recurrences mostly in the mandible (89.47%) with only 2 of 19 
(10.53%) presenting in the maxilla thus corroborating the findings of previous studies 
(Olaitan et al., 1993; Reichart et al., 1995). Comparison of the findings with those of Hong et 
al., (2006), confirms that the association between the risk of recurrence and the location of the 
tumour is not significant.  
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Tumour Size 
 
The impact of socioeconomic factors on demographic features and clinical outcome cannot be 
overemphasised (Butt et al., 2011). In developed countries such as the Netherlands, 
ameloblastomas are often diagnosed early during routine radiographic examination as an 
incidental finding (Hertog et al., 2012). Tumours reported in African and Asian literature tend 
to be larger than those reported in other regions of the world (Adekeye et al., 1986; Olaitan et 
al., 1998; Adebayo et al., 2011). Factors contributing to the larger size include delay in 
presentation, often following consultation with traditional healers or patients seeking medical 
attention only when aesthetically and/or functionally compromised, limited access to 
healthcare services; refusal of treatment, skill shortage, lack of adequate facilities, low 
socioeconomic status and level of education (Simon et al., 2005; Adebayo et al., 2011). 
In accordance with several African studies most tumours (85%) were larger than 4 cm in 
greatest diameter and involved both the anterior and posterior regions of the affected jaws. 
Santos et al., (2014), in their Brazilian study, reported tumour diameters ranging from 3.0 - 
6.9 cm in 63% of 112 ameloblastomas reviewed while Dandriyal et al., (2011), observed 
tumour sizes between 4 and 8 cm. Fifty percent of tumours in a study by Ruhin-Poncet et al., 
(2011) were 5 to 13 cm in greatest diameter. A Tunisian study documented a mean tumour 
size of 4 cm, a range of 5-15 cm (Ahlem et al., 2015) and smaller than the average tumour 
size of 4.3 cm and maximum size of 24 cm reported by Reichart et al., (1995) in one of the 
largest reviews of ameloblastomas. Carlson and Marx (2006) cautioned that large tumours 
complicated by airway compromise and metabolic abnormalities may be potentially life 
threatening. Similar to Abdel-Aziz and Amin (2012) who reported a higher recurrence rate in 
large ameloblastomas, most recurrences in this study occurred in tumours larger than 4 cm.  
Nonetheless, in both studies, this finding did not translate to a statistically significant risk of 
recurrence in relation to the size of the tumour.  
 
At the time of treatment, 93% of the ameloblastomas had perforated the bone leading to 
supraperiosteal dissection and soft tissue encroachment. This finding may be due to the large 
tumour size at the time of treatment. The larger the tumour, the greater the risk of cortical 
perforation and subsequent soft tissue infiltration.  In contrast, a study conducted in Thailand 
reported bone perforation in only 6,7% of their ameloblastomas (Intapa, 2017).  
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Ameloblastoma variants 
 
The solid/multicystic ameloblastoma was the most common variant (76.8%) followed by 
unicystic (16.7%), peripheral (1%) and malignant ameloblastoma (1%). The present findings 
are consistent with other research which found similar relative frequencies for the different 
ameloblastoma variants. Adeline et al., (2008) and Santos et al., (2014) reported slightly 
higher relative frequencies for solid/multicystic ameloblastoma at 83% and 83.8% 
respectively, while the former reported a relative frequency of, 5.3% for unicystic 
ameloblastoma and 0.5% for peripheral ameloblastoma, the latter reported a higher relative 
frequency of 15.3% for unicystic ameloblastoma and 0 % for peripheral ameloblastoma. Siar 
et al., (2012), in a retrospective analysis of 340 cases in a Malaysian population, reported 
65%, 28% and 0.6%   solid/multicystic, unicystic and peripheral ameloblastomas respectively.  
 
Histological type of Ameloblastoma 
 
Solid/multicystic ameloblastoma may show follicular and plexiform growth patterns and 
varied histological types including basaloid, granular, acanthomatous, and desmoplastic 
(Kramer et al., 1992). In the current study, the growth pattern was specified in 56 (29.63%) of 
189 multicystic ameloblastomas. In agreement with studies conducted in America (Waldron 
et al., 1987; Tanzania (Simon et al., 2005); Nigeria (Odukoya et al., 2008; Chukwuneke et al., 
2016), France (Ruhin-Poncet et al., 2011), and Tunisia (Ahlem et al., 2015), the follicular 
growth pattern was more common than the plexiform, although, most tumours with a 
specified growth pattern showed a mixed follicular-plexiform (n= 26, 46.43%) growth 
pattern. In contrast some studies have reported the plexiform as the more common growth 
pattern (Kim and Young., 2001; Nakamura et al., 2002; Tawfik et al., 2010; Saghravanian et 
al., 2017). 
 
Ameloblastoma Growth Patterns 
 
Ueno et al., (1989), Nakamura et al., (2002) and Ruhin-Poncet et al., (2011) reported 
significantly higher recurrence rates in follicular ameloblastoma than in plexiform 
ameloblastoma. Hong et al., (2007) reported a statically significant association between the 
risk of recurrence and the follicular growth pattern as well as the granular and acanthomatous 
histological types of ameloblastoma. In contrast, no significant association was demonstrated 
between recurrence and growth patterns in this study. Additionally, the histology type was of 
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no prognostic significance and was specified in 28 (41.81%) of 189 multicystic 
ameloblastomas, which included granular (20), basal (6), acanthomatous (2) and desmoplastic 
(1) ameloblastoma. There is general consensus that ameloblastoma histology type is not a 
predictor of biological behaviour or recurrence. These results parallel those of numerous 
studies including Pogrel et al., (2009) and Hertog at el., (2012). Conversely, Carlson and 
Max, (2006) stated that the histological type may be an important prognostic indicator. 
 
Surgical treatment methods 
 
The mainstay of treatment for ameloblastoma is surgical intervention comprising radical or 
conservative approaches (Effiom et al., 2017).  Radical treatment encompasses marginal, 
segmental or complete resection with a margin of 1-1.5 cm. Adebayo et al., (2011) suggested 
a margin of 1.5 -2 cm for maxillary ameloblastomas. Conservative treatment includes 
enucleation without adjuvant therapy, enucleation with peripheral ostectomy, cryotherapy or 
Carnoy’s solution as adjuvant therapy or on its own. Different authors advocate different 
treatment options based on a number of factors including ameloblastoma variant, size of the 
lesion and age of the patient. The choice of surgical treatment is an important factor in 
predicting the risk of recurrence, even more so if the primary ameloblastoma is inadequately 
removed (Rastogi et al., 2010). Recurrence is therefore perceived to be indicative of failure of 
the initial tumour treatment (Mosadomi et al., 1975; Demeulemeester et al., 1988; Olaitan et 
al., 1993; Hong et al., 2007; Adebayo et al., 2011). The choice of treatment is often a balance 
between adequate removal of tumour to prevent recurrence and preservation of adjacent tissue 
to minimise morbidity attributable to complications associated with aesthetics, function and 
psychological well-being of the patient (Hong et al., 2007). Researchers, who advocate the 
radical approach, consider the locally aggressive nature of ameloblastoma as intermediate 
between benign and malignant neoplasms (Hong et al., 2007).  Slootweg and Muller (1984) 
recommended radical treatment following observation of metastases post conservative 
management of primary ameloblastomas, hence the recommendation of a radical approach by 
the authors. Sampson and Pogrel (1999) and Dandriyal et al., (2011) advocate radical 
treatment following the observation of high recurrence rates in conservatively managed 
tumours. As proponents of conservative management, Sammartino et al., (2007) and Feinberg 
et al., (1996) argue that although ameloblastomas are locally aggressive, they are benign 
tumours, they rarely metastasise and should therefore be treated accordingly. Furthermore, the 
authors are of the view that the significant morbidity associated with radical treatment is not 
justifiable. For these reasons Sammartino et al., (2007), McClary et al., (2015) and Haqa et 
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al., (2016) support conservative management for ameloblastomas irrespective of size or 
variant. 
 
The choice of treatment in this sample was mainly determined by the size of the tumours. Due 
to the large, infiltrative and expansive nature of tumours at the time of presentation, most 
were treated radically either by complete (86.6%) or marginal (1.2%) resection. This practice 
is in line with a recommendation by Antonoglou and Sandor (2015) to treat smaller tumours 
conservatively and larger tumours or solid/multicystic ameloblastomas radically. Dandriyal et 
al., (2011) and Kovács et al., (1999) advocated radical resection for large expansive tumours 
as seen in this study. Most tumours had perforated the cortical bones with subsequent 
infiltration of the adjacent soft tissue and were therefore treated by radical resection. Of the 
conservatively treated tumours, most were treated by enucleation with peripheral ostectomy. 
According to Hong et al., (2007) the association between the treatment of choice and the risk 
of recurrence is statistically significant; this result is in agreement with the findings in this 
study. 
 
Factors associated with ameloblastoma recurrence include inadequate surgical removal of the 
primary tumour and the resultant infiltration of adjacent tissue by residual tumour cells (To et 
al., 2002), tumour growth patterns and histological types, (Hong et al., 2007), method of 
surgical treatment (Hertog et al., 2010), and local invasiveness (Ribeiro et al., 2009: Zhang et 
al., 2010). In the maxilla, site of tumour involvement, root resorption, and infiltration of 
maxillary antrum are associated with increased risk of recurrence (Yang et al., 2017). 
 
Robinson et al (1977) reported a lower recurrence rate for conservatively treated unicystic 
ameloblastomas than multicystic ameloblastoma. Muller et al., (1985) confirmed these 
findings when they reported recurrence rates of 75% and 20% following conservative 
treatment of multicystic and unicystic ameloblastomas respectively. In a key systematic 
review and meta-analysis of recurrence rates in ameloblastoma Almeida et al., (2016) 
documented a 3.15-fold greater relative risk of recurrence following conservative treatment of 
multicystic ameloblastoma compared to radical treatment. In the current study, of the 7.7% 
(19 of 246) ameloblastomas that recurred, 3 (11%) and 16 (89%) were in primary unicystic 
and multicystic ameloblastomas respectively. This finding supports previous research which 
documented the highest rate of recurrence in multicystic ameloblastomas (Ueno et al., 1989; 
Nakamura et al., 2002; Hong et al., 2007; Antonoglou and Sandor., 2015).  Although Olaitan 
et al (1998) reported a comparable overall ameloblastoma recurrence rate of 8.9% in Nigeria; 
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the authors did not distinguish the rate of recurrence between unicystic and multicystic 
variants.  
 
Histological Margins 
 
Tumours were resected with margins of 1-2cm; the margins were assessed histologically to 
confirm complete removal of tumour.  Logistic regression was performed to determine the 
association between the variables investigated and recurrence. The association between 
histological margins and recurrence was statistically significant (p value = 0.002). 
Histological margins had 0.08 likelihood to be associated with recurrence at 95% CI. To et al 
(2002) reported a similar finding; inadequate surgical removal of tumour is associated with a 
risk of recurrence.  
 
More recurrences are seen in primary bone than in soft tissue. Adebayo et al., (2011) reported 
a case that recurred in soft tissue 21 years after radical resection. Four (19%) of 21 
recurrences reported by Olaitan et al., (1998) were in soft tissue and 17(81 %) in bone. 
Arotiba et al., (2007) documented 4/30 (13.3%) recurrent ameloblastomas. Contrarily, most 
recurrences in this study occurred in soft tissue (53%) followed by 31% in primary bone and 
15.79% in grafted tissue. Although not as common, recurrences in bone grafts have been 
reported by Choi et al., (2006) and Eckardt et al., (2009).  
 
In our sample, 42% and 79% recurrences occurred within 5 and 10 years of treatment of the 
primary tumour.  The mean follow-up period (7, 5 years) is lower than the 10.5 years reported 
by Hertog et al., (2012) and consistent with numerous studies with inadequate follow up 
periods. Although recurrences can occur up to 50 years after treatment of the primary tumour, 
50% occur within 5 years of the primary surgery (Muller and Slootweg, (1985); Reichart et 
al., 1995; Kim and Jang., 2001; Pogrel et al., 2009; Hertog et al., 2012). Olaitan et al., 1998 
reported 80% recurrence within the first five years. Morita et al., (2013) reported two cases 
that recurred 40 and 50 years after radical treatment of the primary ameloblastomas.  These 
late recurrences have led to recommendations of life long follow up periods (Reichart et al., 
1995; Olaitan et al., 1998; Adebayo et al., 2011) 
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4.2 Limitations 
 
Missing data compromised the study, particularly the evaluation of histological types. The 
follow up period was inadequate with most patients lost to follow up, however this is a 
frequently reported limitation in similar studies. A small number of ameloblastomas were 
treated conservative thus compromising the analysis in this subgroup 
 
4.3 Conclusion 
 
Our findings are in agreement with most published studies with regard to demographic data 
and clinico-pathological features of ameloblastoma. Multicystic ameloblastoma is associated 
with a higher risk of recurrence than other variants. We therefore recommend marginal 
resection of smaller multicystic ameloblastoma. Enucleation with peripheral ostectomy was 
effective treatment approach for small unicystic ameloblastoma.  Prior to adoption as standard 
protocol, more studies with large sample sizes and long-term follow-up are recommended. 
Statistically significant associations were identified between histological margins and 
recurrence as well as between surgical procedure and recurrence. We therefore recommend a 
radical approach with resection margins of 1 to 2 cm as the treatment of choice for larger 
tumours. 
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ANNEXURE A.  
Proforma 
 
Patient code……………………… 
 
 
Age    
 
Gender   Male Female 
 
 
Ameloblastoma   
 
Site   Mandible Maxilla skull 
 
 Location   anterior Posterior 
 
 Size   Less than 4cm Greater than 4cm 
 
 Involvement of the inferior border (mandible)   Yes No 
 
 
 Bone perforation 
 
  Yes No 
 
 
Type 
 
 Unicystic  Multicystic Peripheral 
 
Subtypes unicystic 
 
 Luminal  Intraluminal Mural 
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Subtypes multicystic 
 
Growth pattern   
 
Follicular 
 
Plexiform 
 
 
Histopathology 
type 
  
 
Basal 
 
Granular 
 
Acanthomatous 
 
Desmoplastic 
 
 
 
 
 
Treatment option (procedure and year) 
 
 
 Enucleation 
Enucleation and     peripheral 
ostectomy 
Enucleation, peripheral ostectomy and 
cryotherapy 
 
 
Marginal resection  Complete resection Year: 
 
 
Histological margins 
 
 
 
 Bone  Clear Not clear 
 
 
Soft tissue  Clear Not clear 
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Site with close margins 
 
 Buccal   Lingual Inferior 
 
 Proximal  Distal 
 
 
Recurrence 
 
 
 Yes   No 
 
Site of recurrence 
 Primary bone   Soft tissue Grafted tissue 
 
Time between primary surgery and recurrence   
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ANNEXURE C 
Letter of approval from the Head of Oral Health Sciences/Wits Oral Health Centre 
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ANNEXURE D 
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ANNEXURE E  
Patient identifier 
 
Patient code……………………………………………. 
Patient Name…………………………………………. 
Medical record number / File number………………… 
Laboratory Number………………………………….... 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
